Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bile Duct Neoplasms | 3 | 2024 | 111 | 1.590 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 110 | 1.590 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1560 | 0.880 |
Why?
|
| Pancreatic Neoplasms | 5 | 2024 | 698 | 0.850 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 78 | 0.820 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 34 | 0.680 |
Why?
|
| Phenylurea Compounds | 1 | 2020 | 52 | 0.660 |
Why?
|
| Immunoconjugates | 1 | 2020 | 39 | 0.660 |
Why?
|
| Radiosurgery | 1 | 2021 | 113 | 0.650 |
Why?
|
| Clinical Protocols | 1 | 2020 | 240 | 0.620 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 221 | 0.590 |
Why?
|
| Pyrimidines | 1 | 2020 | 389 | 0.540 |
Why?
|
| Patient Selection | 1 | 2020 | 703 | 0.510 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 154 | 0.500 |
Why?
|
| Proteome | 3 | 2012 | 257 | 0.480 |
Why?
|
| Lithostathine | 1 | 2013 | 2 | 0.430 |
Why?
|
| CA-19-9 Antigen | 1 | 2013 | 10 | 0.430 |
Why?
|
| Melanoma | 1 | 2021 | 943 | 0.430 |
Why?
|
| Translocation, Genetic | 2 | 2020 | 359 | 0.400 |
Why?
|
| Pancreatic Juice | 1 | 2011 | 5 | 0.370 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1324 | 0.370 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 85 | 0.360 |
Why?
|
| Carrier Proteins | 2 | 2013 | 1031 | 0.350 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1558 | 0.300 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 42 | 0.300 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 338 | 0.300 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2008 | 124 | 0.270 |
Why?
|
| Deoxycytidine | 3 | 2023 | 80 | 0.260 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2024 | 99 | 0.260 |
Why?
|
| Rhabdomyosarcoma | 1 | 2008 | 193 | 0.250 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 687 | 0.240 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2024 | 5 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 122 | 0.200 |
Why?
|
| Mucoproteins | 2 | 2013 | 12 | 0.200 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2022 | 18 | 0.190 |
Why?
|
| Oncogene Proteins | 2 | 2013 | 143 | 0.190 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2021 | 4 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 378 | 0.180 |
Why?
|
| ROC Curve | 2 | 2013 | 577 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1253 | 0.170 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 11 | 0.160 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2019 | 12 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 2546 | 0.160 |
Why?
|
| Humans | 17 | 2024 | 126366 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 1258 | 0.160 |
Why?
|
| Cisplatin | 1 | 2020 | 251 | 0.150 |
Why?
|
| Neoplasms | 2 | 2012 | 2814 | 0.150 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 242 | 0.150 |
Why?
|
| Mutation | 2 | 2024 | 5961 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2019 | 193 | 0.140 |
Why?
|
| Proteins | 2 | 2013 | 1045 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 1031 | 0.130 |
Why?
|
| Research Design | 1 | 2020 | 709 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2021 | 683 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 560 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16522 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 2901 | 0.120 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2013 | 11 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 1789 | 0.100 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 3458 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2011 | 1996 | 0.100 |
Why?
|
| Receptors, Polymeric Immunoglobulin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Collagen Type IV | 1 | 2011 | 22 | 0.090 |
Why?
|
| Ascites | 1 | 2011 | 95 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 91 | 0.090 |
Why?
|
| Pancreas | 1 | 2011 | 222 | 0.090 |
Why?
|
| Limit of Detection | 1 | 2009 | 63 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1293 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1297 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 668 | 0.080 |
Why?
|
| Biomarkers | 2 | 2023 | 3154 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 12 | 0.080 |
Why?
|
| PAX3 Transcription Factor | 1 | 2008 | 29 | 0.080 |
Why?
|
| Paired Box Transcription Factors | 1 | 2008 | 75 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 137 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 140 | 0.070 |
Why?
|
| Proteomics | 1 | 2011 | 514 | 0.070 |
Why?
|
| Computational Biology | 1 | 2012 | 838 | 0.070 |
Why?
|
| Age Factors | 1 | 2013 | 2836 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3343 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 364 | 0.060 |
Why?
|
| Middle Aged | 4 | 2022 | 27046 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 58 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2024 | 226 | 0.050 |
Why?
|
| Aged | 3 | 2019 | 19978 | 0.050 |
Why?
|
| Brazil | 1 | 2022 | 124 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2825 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2021 | 38 | 0.050 |
Why?
|
| Adult | 3 | 2021 | 29800 | 0.050 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2021 | 21 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 110 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 189 | 0.040 |
Why?
|
| Female | 5 | 2022 | 67337 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 888 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 579 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 250 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 347 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 515 | 0.040 |
Why?
|
| Male | 4 | 2021 | 62042 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 551 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1075 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 787 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2023 | 12386 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 744 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1021 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2071 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 900 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5202 | 0.020 |
Why?
|
| Prognosis | 1 | 2019 | 4734 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 477 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 6177 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6652 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2021 | 14207 | 0.020 |
Why?
|